Elliott Builds \$2.5 Billion Bio-Rad Stake, Activist Target Confirmed
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Elliott Management has built a sizeable stake in medical technology firm Bio-Rad Laboratories. The Wall Street Journal reported the activist investor's position on May 18, 2026. The investment is estimated to be worth more than \$2.5 billion, representing one of Elliott's largest healthcare positions this year. This development places Bio-Rad, a company with a \$11.3 billion market capitalization, firmly in the sights of a shareholder activist known for pushing for operational changes and strategic reviews. The news follows a multi-year period of underperformance for Bio-Rad's stock relative to its sector peers.
Activist campaigns in the healthcare sector have intensified following the post-pandemic normalization of capital flows. The last comparable major stake in a life sciences tools company occurred in October 2025 when Starboard Value took a position in Agilent Technologies, ultimately leading to a \$3 billion accelerated share repurchase program. The broader life sciences tools sector, tracked by the SPDR S&P Biotech ETF, has declined 12% year-to-date through mid-May 2026, underperforming the S&P 500's 5% gain.
The immediate catalyst for Elliott's interest is Bio-Rad's complex capital structure and significant non-core assets. Bio-Rad holds a 26% stake in drug diagnostics firm Qiagen, valued at approximately \$3.1 billion. This holding constitutes a substantial portion of Bio-Rad's own market value, creating a persistent conglomerate discount. Elliott likely sees unlocking this value as a primary lever for shareholder returns, alongside potential operational improvements in Bio-Rad's core diagnostics and life sciences businesses.
Bio-Rad Laboratories' stock closed at \$311.45 on May 17, 2026. The company's market capitalization stands at \$11.3 billion. Bio-Rad's stock performance has lagged the iShares US Medical Devices ETF by 18 percentage points over the past three years. The firm's revenue for fiscal year 2025 was \$2.85 billion, a decline of 4% from the prior year.
Elliott's reported stake exceeds \$2.5 billion, equating to a holding of roughly 22-25% of Bio-Rad's outstanding shares. The investment firm manages over \$65 billion in assets. A comparison of key valuation metrics highlights Bio-Rad's discount.
| Metric | Bio-Rad | Sector Median |
|---|---|---|
| Price-to-Sales (TTM) | 4.0x | 5.8x |
| Enterprise Value/EBITDA | 14.2x | 18.1x |
| Gross Margin | 57.1% | 59.5% |
The company's Qiagen stake alone is worth \$3.1 billion, implying the market values Bio-Rad's core operations at just \$8.2 billion.
The Elliott stake directly pressures Bio-Rad's management to initiate a formal review of its Qiagen holding. A full or partial sale of this stake could return significant capital to shareholders via a special dividend or buyback, potentially providing a 15-25% near-term uplift to Bio-Rad's stock price. Companies like Danaher and Thermo Fisher Scientific, which have historically acquired assets in this space, could see renewed speculation as potential buyers for Bio-Rad assets, providing a tailwind to their shares.
Sector peers like Waters Corporation and PerkinElmer may experience secondary pressure as investors scrutinize their portfolios for similar non-core holdings or operational inefficiencies. A key counter-argument is that Bio-Rad's family-controlled voting structure, with the Schwartz family holding supervoting Class B shares, could limit Elliott's ability to force immediate board changes or a breakup. The flow of capital is moving towards specialized, pure-play life sciences firms and away from conglomerate structures, as evidenced by recent gains in stocks like Repligen.
The primary near-term catalyst is Bio-Rad's formal response, expected via a press release or regulatory filing before its Q2 earnings call in late July 2026. Investors will monitor for the announcement of a strategic review committee or the engagement of financial advisors. A key level to watch is the \$340 share price, which represents the stock's 2025 high; a break above this resistance would signal market confidence in imminent action.
The quarterly earnings report from Qiagen, scheduled for July 29, 2026, will be critical for assessing the valuation of Bio-Rad's largest asset. Any guidance change from Qiagen could materially shift the calculus for a potential divestiture. SEC filings from Elliott will reveal the exact size of its position and whether it has designated the stake as passive or activist, which typically occurs within 10 days of crossing the 5% ownership threshold.
Bio-Rad currently pays a nominal quarterly dividend of \$0.18 per share, yielding about 0.23%. Elliott Management typically prioritizes maximizing total shareholder return over incremental dividend increases. The firm is more likely to advocate for a large, one-time capital return event funded by asset sales, such as the Qiagen stake, rather than a sustained hike in the regular dividend. This approach aims to deliver a more immediate and substantial return of capital.
Elliott's 2023 campaign at Salesforce involved pushing for cost discipline, margin improvement, and a renewed focus on profit growth, leading to board seats and significant restructuring. The Bio-Rad situation is structurally different, centered on unlocking value from a large, non-core publicly-traded equity holding. The playbook here is more akin to Elliott's historical involvement with companies like Cognizant, where portfolio simplification was a primary goal, rather than a pure operational turnaround.
Academic studies and sector analysis show a mixed record. A 2024 review by Fazen Markets of 15 activist campaigns in the healthcare equipment sector from 2020-2025 found an average 12-month outperformance of 9% versus the sector index following the initial stake disclosure. However, success heavily depends on the activist's ability to catalyze a specific transaction, like a spin-off or sale. Campaigns that result in asset sales or breakups have delivered median returns of 22%, while those focused solely on operational tweaks have averaged just 4%.
Elliott's massive stake has triggered an unavoidable strategic reckoning for Bio-Rad, centering on the fate of its \$3.1 billion Qiagen holding.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.